CAC2 Childhood Cancer Community News Digest (June 5-11)

Assorted News from the Last Week:

National Comprehensive Cancer Network releases statement addressing ongoing chemotherapy shortages.

Childhood cancer survivors at increased risk for sleep concerns decades after diagnosis

CAC2 Supporting Organization Fennec Pharmaceuticals announces European Commission marketing authorization for Pedmarqsi™ (sodium thiosulfate) to reduce the risk of hearing loss in pediatric oncology patients.

Adding the drug blinatumomab (Blincyto) to chemotherapy may help more infants with acute lymphoblastic leukemia (ALL) survive, according to the results of a small international clinical trial.

Parents of children in palliative care placed the highest value on the child’s quality of life (QoL), but with considerable individual-level variation and substantial change over time.

Treatment with tovorafenib (DAY101) elicited encouraging and fast onset responses in heavily pretreated pediatric patients with low-grade glioma regardless of response assessment criteria, according to data from the phase 2 FIREFLY trial (NCT05566795) that were presented at the 2023 ASCO Annual Meeting.

This month, as part of International Cancer Survivors Month, Cansa celebrates all cancer survivors and salutes their perseverance with a focus on children, teens, young adults and parents or guardians.

Upcoming Webinars, Online Opportunities, and Meetings:

Join us at the CAC2 2023 Annual Summit, presented by Day One Biopharmaceuticals! This year’s conference takes place from noon, Monday, June 19 through 2:00 pm, Wednesday, June 21, 2023, in Atlanta, GA, at Children’s Healthcare of Atlanta Emory University.  Click here for more information and to register.

Triage Cancer will present a webinar: Cancer & Disability Insurance on June 21, 2023, 11:30-1:00 ET.  This webinar will explore potential disability insurance options for those that need to take time off work after a cancer diagnosis (including options for caregivers). Click here for more information and to register.

MIB Agents Osteosarcoma Alliance FACTOR 2023 Conference brings together the leading osteosarcoma researchers and clinicians, along with patient families and OsteoWarriors (survivors, patients and siblings of OsteoWarriors and OsteoAngels) to Make It Better for those battling this disease.  Click here for more information.

Give Kids the World Summer Road Trip! From June 17-26, GKTW visit 10 amusement parks and offer a day of fun for our incredible Alumni families for free.  Summer Road Trip info can be found here:  https://www.gktw.org/roadtrip/.

Rocky Mountain Vintage Racing is pleased to announce a 2-year festival series culminating in 2023 with the FV 60th anniversary. RMVR’s Race Against Kids’ Cancer (RAKC), will be at High Plains Raceway where these wonderful cars of all years and vintages are invited to gather to celebrate this class. Click for more information about Vintage Car Races for Fundraising.

Registration for CureFest 2023 is now open! Register today at:  www.curefestusa.org

Take Action:

Pediatric Cancer legislation needs your support.  Learn more about how to support the Gabriella Miller Kids First Research Act 2.0, the Sawyer Finn ACT, and the Give Kids a Chance Act.

The International Agency for Research on Cancer (IARC) and partner institutions are now accepting applications for an online course on the registration of cancer in children.  Click here for more information.

Do you have an idea for solving the market failure problem that leads to no or slow drug development for children with cancer?  Check out the MSA Innovation Challenge 2023:  The submission template asks applicants to identify a market failure where the social value exceeds private incentives and where we know the measurable outcome we want to encourage (e.g. the development of a vaccine, capturing carbon out of the air, etc.).  Click here for more information.

SUBSCRIBE

Sign up to receive a copy of CAC2's free childhood cancer news digest in your inbox each week.

Name(Required)
Email(Required)
This field is for validation purposes and should be left unchanged.